TMEM71: A Transmembrane Protein Identified as a Potential Drug Target and Biomarker

Target Name: TMEM71

NCBI ID: G137835

TMEM71

TMEM71: A Transmembrane Protein Identified as a Potential Drug Target and Biomarker

TMEM71 (Transmembrane protein 71, isoform 1) is a gene encoding a protein that is expressed in various tissues and organs, including brain, heart, lungs, and gastrointestinal tract. TMEM71 has unique characteristics, such as its transmembrane nature and various isoforms, which make it an interesting protein for research and potential drug development. In this article, we will explore the biology and potential drug targets of TMEM71.

Background

TMEM71 is a member of the transmembrane protein family, which includes proteins that span the cell membrane and extend into the cytoplasm or cell lumen. These proteins play a vital role in cellular signaling, structure, and function. TMEM71 is characterized by its transmembrane structure and various isoforms, which are important factors influencing its function in different cellular contexts.

TMEM71 isoforms have distinct differences in their extracellular domains, which result in different functions. For instance, isoform 1 has a unique N-terminus that is involved in interaction with various signaling pathways, including the TGF-β pathway. This feature makes TMEM71 iso1 a potential drug target for several therapeutic applications.

Drug Target Potential

TMEM71 is a promising drug target due to its unique features and the involvement of various signaling pathways. One of the primary drug targets for TMEM71 is the TGF-β pathway, which is involved in cell growth, differentiation, and survival. Activation of the TGF-β pathway has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

Several studies have shown that TMEM71 is involved in TGF-β signaling in various cellular contexts. For example, TMEM71 has been shown to be a positive regulator of the TGF-β1 receptor, which is a key mediator of the TGF-β pathway. Additionally, TMEM71 has been shown to play a role in the regulation of cell proliferation and survival, which are crucial functions for cancer and neurodegenerative disorders.

Biomarker Potential

TMEM71 isoform 1 has also been shown to be a potential biomarker for several diseases. For instance, TMEM71 has been shown to be involved in the regulation of cancer cell survival and angiogenesis, which are critical processes for tumor progression. Additionally, TMEM71 has been shown to be involved in the regulation of inflammation and cellular immune responses, which are important for diseases such as autoimmune disorders and inflammatory bowel diseases.

Conclusion

TMEM71 is a unique protein that exhibits various characteristics that make it an interesting potential drug target and biomarker. Its transmembrane nature and various isoforms have unique features that influence its function in different cellular contexts. The potential drug targets for TMEM71 include the TGF-β pathway and cell proliferation, while its potential biomarkers include cancer cell survival, angiogenesis, inflammation, and cellular immune responses. Further research is needed to fully understand the biology and potential drug targets of TMEM71, which could lead to new therapeutic applications for various diseases.

Protein Name: Transmembrane Protein 71

The "TMEM71 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM71 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets